FibroGen Inc expected to post a loss of 42 cents a share - Earnings Preview

Kyntra Bio

24/02/2024 01:14

* FibroGen Inc  FGEN.OQ   FGEN.O  is expected to show a rise
in
quarterly revenue when it reports  results on February 26 for
the period ending December 31 2023
    * The San Francisco California-based  company is expected to
report a 13.2% increase in revenue to $38.901 million from
$34.37 million a year ago, according to the mean estimate from 2
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for FibroGen Inc is for a
loss
of 42 cents per share. 
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for FibroGen
Inc is
$1.25​, below​ its last closing price of $1.82. ​​​

This summary was machine generated February 24 at 01:14 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)